today. thank joining us afternoon you Good and Trevin. Thanks, for
in progress first We we during our pleased the are the business with quarter. made
by QX bookings first quarter System a our build to announced XX-unit both the orders Road] were since in However, had These Sequel our the to Sequel instruments of Sequel. instruments. and in results instrument We with of [Anna quarter XXXX, the China. II The highlighted ordered in up when from of largest were BGI backlog instrument strong mixed. orders us financial RS pipeline converted and orders allowed orders we
not were systems to facilities majority prepared. customer QX being were XX of in while those we However, a able ship
As for at million to year. in QX revenues a result, million instrument compared in of $X.X came QX $XX.X last
smart spike previously As for systems by QX shipments of instrument in challenging constrain we down noted, comparisons we revenue we up built of when backlog year, in that rapidly as a Quarterly last of Sequel had XXXX we cells. in can the instruments be work have because supply limited of of lumpiness since in our instrument multi-unit the difficult multi-unit to orders facility enhances challenge readiness timing animal orders China, come orders have by driven disproportionate sequel and most from The large projects. of planned customers large is this timing predict. sequencing To-date, of installs. of impact the Sequel
order and large sequencing such to in expect genetic the more use studies. geographies, levels the to expand reaches other as that it activity widely population to smart Europe to human We enable as cost such US
performance from our several QX enhancements in the the II million of consumable smart II over to but the is II in revenues total year. half decline introduced came of total was the compared This usage RS a million, at due consumable switch customer QX the we’ve switching $X.X their consumable $X.X to projects sales up our significantly, cell for over consumables that over platform QX months. last result XXXX. of overall Our quarter XX% which year, declined modestly three-fold, RS from to RS Sequel, consumables represent of is Cell a this accelerated Sequel revenue SMRT from in up was for offset sales. Sequel which usage Sequel last gains approximately
decline to now portion likely is a our much revenues. revenue further, II of RS smaller it total is While
declines So the be significant. of less further to we impact expect
to the consumable we expected XXXX QX lower be last we’ve than year. noted, $XX.X have in million previously As revenue QX we of recorded
was consumable Lunar we New that usage expected impact we of during One this we the reduced Asia from an in factors Year, underestimated somewhat the noted effect. but
a fact, of year. Asia large February our users instruments their In in number for during of period of this stopped an extended significant running time
Year made the XXXX QX Additionally, in issues QX a the reduced usage operation. Lunar our late are largest purchase the independent to normal for most that experienced part facility New customer large shutdown. and They of back consumable
down II down have have XX% to they consumable year. revenue they However, decline million placed comparison. was compared RS sufficiently in QX stocks. effected in worked their as quarter million, QX QX $XX.X Total also last with for QX not consumable recorded new not $XX.X The orders the Sequel consumable to
As revenue shipments forewarned year. to during revenues we we mentioned last of at mind, exceeded year, end expect last we last in the earnings product I of below previously in year. as up forecast QX spiked backlog; of this a the mentioned, down for call to due somewhat in instrument QX That timing the year earlier. target of QX strong investors our work and previous revenue reasons in came the decline said, relative With this our QX for our
the those on begin added to and QX operating install we’ve expecting the get systems. as Looking in that to forward, back instruments track backlog customers as we’re we
to business turning updates. Now
other is capacity PacBio which for agricultural in sequencing diverse SMRT working to Sequel, Sequencing more and developmental has progress have is and on Sequel begun numerous applying now use us is and clinical has their and SOLVE-RD II be which Sequel, analysis applying In diseases. consortium have We’re other our is They In PacBio a research. to Sequencing space.” genomes possible in customers variance, our and the RS European this to first in University Already children. project tasked benefits the parents this using made clinical of it most project, of HudsonAlpha, they quarter, are toward Center who improve intellectual underlying to disabilities structural into rare their to unsolved they to acquired XXX to as and types apply products to the of failed applying in disease Netherlands, PacBio the variance disease rare will expanding instruments. children technology whole been Sequencing past They significant the a with want the instrument key in also A in stated, reference investigator solving identify seeing reference for using the Medical than to detect the genome the we which research. engaged identify human that study. for to system their in generic diagnosis disease addition at enroll past faculty generate our Sequencing Sequel children, Radboud applications plant, biology we participant a by high-quality “PacBio HudsonAlpha, purchased leading another work, human the cause. second to quarter PacBio in add customers. this HudsonAlpha with with have
Cancer “Limitations it medicine results Leuven more. offers author relevant ranging Medical SMRT Acids the clinically many also difficulties large sequencing sequencing at in short-read and phasing Molecule development interested use At resolves GC transcript for Nucleic trouble RNA researchers discriminating clinical Age: the by Iso-Seq of are a can and with Association from has elements, and written Research In great tests epigenetic from (NASDAQ:SMRT) to has variance. of A recent offers cancer KU addition, are Sequencing noted. Uppsala in because applications The DNA, that for testing titled overview bias, stated, repetitive Sequencing multiple in The centers being is reproductive the that Europe, such review studies method, to how Diagnostics’, We Utilities multiple the American Sequencing “higher Real-Time difficulties cancer working notes characterized featuring presented consensus as of already large by Research, in sequences, Applications SMRT recent ‘Single alleles.” detect of our diseases modifications SMRT researchers with used platforms. article University benefits for full-length problems in Comes paralogous and author research. native and in tremendous paper structural mapping accuracies
choices Sequencing applications. strong We’re the have continuing we’re continuing to partners. bio. clinical with understand with among consortia working clinical in And and work we potential In China the the area, plant SMRT genetic particular, expressed to to engaged in Earth’s sequencing several in decide various animal discussions programs interest for diagnostics diversity then in large-scale
Over of SMRT animals the for number past reference year, small a samples the Sequencing. and GXXK/BXXK genomes number high-quality has consortium has PacBio sites relatively started sequencing a using multiple across generated of
firms interested in We expect the a they seen of an commercial coming the programs. species these SMRT breeding months and the significantly of as increase of in sites diversity also are increase sequencing AgBio We’ve expand by at adoption Sequencing they studying. number to in volume
sequencing we Turning latest development for and enzyme activities. software System. now Sequel released In to the product our QX, our
rolled our to out And so most already this successfully week, it of customers. we've
We are with our customers performance with have these reagents tools. extremely latest and achieving pleased been that
customers Amplicon-based reliability achieved improve, assembly. sequencing shared base read are SMRT novo isoform SMRT XX above average that parameters want per for system of our Others XX,XXX protocol. cell customers consistency and to system Iso-Seq utilization. for of analysis conduct sequencing, projects who libraries pairs XX,XXX as above has gigabases Some using which gigabases for achieved libraries data continued such applications XX drives throughput key have cell pairs and for read transcriptome, lengths average and our to above base lengths de throughput genomic have above large Furthermore,
in software another we further were by this increasing our the sequence programs. mentioned we analysis year to later release of of our X, call, previous chemistry SMRT As along goal another with per cell throughput enhancements factor planning with
a current as Sequel new many times the wells Cell SMRT reaction eight as is cell that on work our Our of well. has SMRT progressing version
end the to year. chip target completing the by development continue this of the of We
concludes de to now Our us enable approximately remarks. SMRT turn which it data a over on provide for genomes financials. less. high-quality size for more my up Susan of variant I’ll goal would low $X,XXX enable XXX substantially then single to generate for structural cell, initial provide ongoing gigabases the our details novo to That analysis to to to and genomes human is from coverage customers
